View Item 

Show simple item record

TRH attenuates scopolamine-induced memory impairment in humans

dc.contributor.authorCohen, Martin Robert.en_US
dc.contributor.authorWeingartner, Herbert J.en_US
dc.contributor.authorSunderland, Treyen_US
dc.contributor.authorLawlor, Brian A.en_US
dc.contributor.authorCohen, Robert M.en_US
dc.contributor.authorMolchan, Susan E.en_US
dc.contributor.authorMellow, Alan M.en_US
dc.date.accessioned2006-09-11T17:39:02Z
dc.date.available2006-09-11T17:39:02Z
dc.date.issued1990-03en_US
dc.identifier.citationMolchan, Susan E.; Mellow, Alan M.; Lawlor, Brian A.; Weingartner, Herbert J.; Cohen, Robert M.; Cohen, Martin R.; Sunderland, Trey; (1990). "TRH attenuates scopolamine-induced memory impairment in humans." Psychopharmacology 101(1): 84-89. <http://hdl.handle.net/2027.42/46332>en_US
dc.identifier.issn0033-3158en_US
dc.identifier.issn1432-2072en_US
dc.identifier.urihttps://hdl.handle.net/2027.42/46332
dc.identifier.urihttp://www.ncbi.nlm.nih.gov/sites/entrez?cmd=retrieve&db=pubmed&list_uids=2104988&dopt=citationen_US
dc.description.abstractThe brain tripeptide thyrotropin-releasing hormone (TRH) has been demonstrated to facilitate cholinergic neurotransmission. To test its interaction with the cholinergic system in humans, high-dose TRH (0.5 mg/kg) or placebo was administered intravenously (IV) to normal controls pretreated with scopolamine (0.5–0.75 mg IV), a centrally active muscarinic antagonist, which has been used to model aspects of the memory impairment of normal aging and of dementia. Compared to placebo, TRH markedly attenuated scopolamine-induced impairment of some measures of memory, most notably on a selective reminding task. This cognitive study is the first in humans to suggest a neuromodulatory effect of a peptide on the cholinergic system, and suggests a facilitatory role for TRH in human memory processes.en_US
dc.format.extent957712 bytes
dc.format.extent3115 bytes
dc.format.mimetypeapplication/pdf
dc.format.mimetypetext/plain
dc.language.isoen_US
dc.publisherSpringer-Verlagen_US
dc.subject.otherNeuropeptideen_US
dc.subject.otherBiomedicineen_US
dc.subject.otherPsychiatryen_US
dc.subject.otherMemoryen_US
dc.subject.otherPharmacology/Toxicologyen_US
dc.subject.otherThyrotropin-releasing Hormone (TRH)en_US
dc.subject.otherScopolamineen_US
dc.titleTRH attenuates scopolamine-induced memory impairment in humansen_US
dc.typeArticleen_US
dc.subject.hlbsecondlevelPsychiatryen_US
dc.subject.hlbsecondlevelNeurosciencesen_US
dc.subject.hlbsecondlevelChemistryen_US
dc.subject.hlbsecondlevelBiological Chemistryen_US
dc.subject.hlbtoplevelScienceen_US
dc.subject.hlbtoplevelHealth Sciencesen_US
dc.description.peerreviewedPeer Revieweden_US
dc.contributor.affiliationumDepartment of Psychiatry, University of Michigan Medical Center, 1103 East Huron, 48104, Ann Arbor, MI, USAen_US
dc.contributor.affiliationotherDepartment of Psychology, George Washington University, 2125 G Street, N.W., 20036, Washington, DC, USAen_US
dc.contributor.affiliationotherUnit on Geriatric Psychopharmacology, Section on Clinical Neuropharmacology, Laboratory of Clinical Science, National Institute of Mental Health, 9000 Rockville Pike, 20892, Bethesda, MD, USA; National Institute of Mental Health, NIH Clinical Center, Building 10, Room 3D41, 9000 Rockville Pike, 20892, Bethesda, MD, USAen_US
dc.contributor.affiliationotherUnit on Geriatric Psychopharmacology, Section on Clinical Neuropharmacology, Laboratory of Clinical Science, National Institute of Mental Health, 9000 Rockville Pike, 20892, Bethesda, MD, USAen_US
dc.contributor.affiliationotherSection on Clinical Brain Imaging, Laboratory of Cerebral Metabolism, National Institute of Mental Health, 9000 Rockville Pike, 20892, Bethesda, MD, USAen_US
dc.contributor.affiliationotherEnsor Research Laboratory, William S. Hall Psychiatric Institute, University of South Carolina School of Medicine, P.O. Box 202, 29202, Columbia, SC, USAen_US
dc.contributor.affiliationotherUnit on Geriatric Psychopharmacology, Section on Clinical Neuropharmacology, Laboratory of Clinical Science, National Institute of Mental Health, 9000 Rockville Pike, 20892, Bethesda, MD, USAen_US
dc.contributor.affiliationumcampusAnn Arboren_US
dc.identifier.pmid2104988en_US
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/46332/1/213_2005_Article_BF02245795.pdfen_US
dc.identifier.doihttp://dx.doi.org/10.1007/BF02245795en_US
dc.identifier.sourcePsychopharmacologyen_US
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Name:
213_2005_Article_BF02245795.pdf
Size:
935.2KB
Format:
PDF
View/Open

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.